No Data
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Revenue Breakdown
News
Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (For Tilmanocept Immunotherapeutic Applications)"
Navidea Biopharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent App 17/370,920 Titled "Synthesis Of Uniformly Defined Molecular Weight Mannosylated Dextrans & Derivatives Thereof (Fo
Express News | Navidea Biopharmaceuticals Sells Preferred Shares Worth $1.1 Million
Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completion
Navidea Biopharmaceuticals Announced The Sale Of Preferred Shares Totaling $1.1M To New Existing Investors; It Provides Additional Capital To Fuel Navidea's NAV3-32 And NAV3-33 Trials Toward Completio